[1]Patent:US2005/85550,2005,A1.Locationinpatent:Page/Pagecolumn8
[2]Patent:WO2005/46665,2005,A1.Locationinpatent:Page/Pagecolumn10-11
[3]Patent:US2005/222163,2005,A1.Locationinpatent:Page/Pagecolumn28
[1]CurrentPatentAssignee:PFIZERINC-US2005/85550,2005,A1Locationinpatent:Page/Pagecolumn8
[2]CurrentPatentAssignee:PFIZERINC-WO2006/134469,2006,A1Locationinpatent:Page/Pagecolumn10;14-15
[3]CurrentPatentAssignee:PFIZERINC-WO2006/134469,2006,A1Locationinpatent:Page/Pagecolumn11;15
[4]CurrentPatentAssignee:PFIZERINC-US11066358,2021,B1Locationinpatent:Page/Pagecolumn21-22;24-25
[5]CurrentPatentAssignee:SPRINGWORKSTHERAPEUTICS,INC-US11084780,2021,B1Locationinpatent:Page/Pagecolumn96;99-100;102
Title: Barrett SD, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4.
Title: Judith S. Sebolt-Leopold, et al. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential
Title: Henderson YC, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76.